Loading…
Loading…
Key Takeaways Jackson Center, PA, November 3, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development
JACKSON CENTER, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development of an effective post-head-trauma treatment for Traumatic Brain Injury (TBI).
Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies Halberd Demonstrates NeuroSense AI FeasibilityHalberd Corporation successfully validated its NeuroSense AI system in a live demonstration, showcasing advanced multi-modal behavioral analysis technology designed to revolutionize traumatic brain injury (TBI) research and neurological diagnostics.
First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain Injury Recovery Monitoring, Among Other Medical Applications Jackson Center, PA, September 29, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp.
JACKSON CENTER, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp., a groundbreaking artificial intelligence platform that will revolutionize behavioral analysis for traumatic brain injury (TBI) research and clinical assessment.
Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa.
JACKSON CENTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease.
The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award! Key Points: Athena GTX has been awarded a $2,866,000 final development contract from the U.S. government for its Smart Autonomous Critical Care System (S-ACCS).
No recent filings indexed.